Developmental Therapeutics Recent Publications
2024
- VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model.Boisserand LSB, Geraldo LH, Bouchart J, El Kamouh MR, Lee S, Sanganahalli BG, Spajer M, Zhang S, Lee S, Parent M, Xue Y, Skarica M, Yin X, Guegan J, Boyé K, Saceanu Leser F, Jacob L, Poulet M, Li M, Liu X, Velazquez SE, Singhabahu R, Robinson ME, Askenase MH, Osherov A, Sestan N, Zhou J, Alitalo K, Song E, Eichmann A, Sansing LH, Benveniste H, Hyder F, Thomas JL. J Exp Med. 2024 Apr 1; 2024 Mar 5. PMID: 38442272.
- CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.Huang RR, Chen Z, Kroeger N, Pantuck A, Said J, Kluger HM, Shuch B, Ye H. Clin Genitourin Cancer. 2024 Apr; 2023 Dec 13. PMID: 38195301.
- CML and the WHO: Why?Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. J Clin Oncol. 2024 Mar 20; 2023 Dec 12. PMID: 38086008.
- Reply to Pisan et al.: Pathogenicity of inherited TRAF7 mutations in congenital heart disease.Mishra-Gorur K, Barak T, Kaulen LD, Henegariu O, Jin SC, Aguilera SM, Yalbir E, Goles G, Nishimura S, Miyagishima D, Djenoune L, Altinok S, Rai DK, Viviano S, Prendergast A, Zerillo C, Ozcan K, Baran B, Sencar L, Goc N, Yarman Y, Ercan-Encicek AG, Bilguvar K, Lifton RP, Moliterno J, Louvi A, Yuan S, Deniz E, Brueckner M, Gunel M. Proc Natl Acad Sci U S A. 2024 Mar 19; 2024 Mar 11. PMID: 38466853.
- The role of surgery and deescalation for HPV-related oropharyngeal cancer.Contrera KJ, Patel MR, Burtness B, Mehra R, Ferris RL. Cancer. 2024 Mar 18; 2024 Mar 18. PMID: 38497569.
- Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Verma S, Singh V, Nagampalli V, Ponsky LE, Li CR, Chao H, Gupta S. Mol Carcinog. 2024 Mar 14; 2024 Mar 14. PMID: 38482990.
- Enantioselective Sulfonimidamide Acylation via a Cinchona Alkaloid-Catalyzed Desymmetrization: Scope, Data Science, and Mechanistic Investigation.Haas BC, Lim NK, Jermaks J, Gaster E, Guo MC, Malig TC, Werth J, Zhang H, Toste FD, Gosselin F, Miller SJ, Sigman MS. J Am Chem Soc. 2024 Mar 13; 2024 Mar 13. PMID: 38480482.
- Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Target Oncol. 2024 Mar 11; 2024 Mar 11. PMID: 38466534.
- Correction: pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis.Fan Z, Zhou S, Garcia C, Fan L, Zhou J. Nanoscale. 2024 Mar 7; 2024 Mar 7. PMID: 38372010.
- A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. Clin Cancer Res. 2024 Mar 6; 2024 Mar 6. PMID: 38446990.
- Enthalpies and entropies of hydration from Monte Carlo simulations.Jorgensen WL. Phys Chem Chem Phys. 2024 Mar 6; 2024 Mar 6. PMID: 38412420.
- Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Br J Cancer. 2024 Mar 4; 2024 Mar 4. PMID: 38438590.
- Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.Butt A, Christian J, Kress A, Lu BY, Hurwitz ME, Goldberg SB, Podoltsev NA, Gilkes L, Lee AI. J Cancer Educ. 2024 Mar 2; 2024 Mar 2. PMID: 38430454.
- Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: A systematic review and meta-analysis.Silva-Santisteban A, Hernandez Woodbine MJ, Noriega MA, Rabinowitz LG, Grimshaw A, Farrell JJ, Chhoda A, Sawhney MS. Gastrointest Endosc. 2024 Mar 1; 2024 Mar 1. PMID: 38432492.
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Eur J Cancer. 2024 Mar; 2024 Jan 11. PMID: 38295556.
- Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain.Prior D, Sowa A, Pashankar F. J Pediatr Hematol Oncol. 2024 Mar 1; 2024 Jan 25. PMID: 38277626.
- A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.Argiris A, Flamand Y, Savvides P, Johnson JM, Vathiotis I, Levine M, Li S, Forastiere AA, Burtness B. Eur J Cancer. 2024 Mar; 2023 Dec 29. PMID: 38215573.
- Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).Zeidan AM, Mearns ES, Ng CD, Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng WH, Bui CN, Svensson A. Clin Lymphoma Myeloma Leuk. 2024 Mar; 2023 Oct 30. PMID: 37996264.
- Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.Su D, Kluger H, Olino K. Ann Surg Oncol. 2024 Mar; 2023 Nov 21. PMID: 37989956.
- K-t PCA accelerated in-plane balanced steady-state free precession phase-contrast (PC-SSFP) for all-in-one diastolic function evaluation.Xiang J, Lamy J, Qiu M, Galiana G, Peters DC. Magn Reson Med. 2024 Mar; 2023 Nov 6. PMID: 37927206.
- Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow-up.Khajir G, Sun T, Wang H, Sprenkle PC, Adeniran AJ, Cai G, Levi AW. Cytopathology. 2024 Mar; 2023 Nov 2. PMID: 37916579.
- Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma.Hafler D, Lu B, Lucca L, Lewis W, Wang J, Nogeuira C, Heer S, Axisa PP, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair FJ, Kluger H. Res Sq. 2024 Feb 28; 2024 Feb 28. PMID: 38464315.
- pHLIP targeted intracellular delivery of calicheamicin.DuPont M, Klumpp C, Iraca M, Allababidi D, Visca H, Engelman DM, Andreev OA, Moshnikova A, Reshetnyak YK. Int J Pharm. 2024 Feb 28; 2024 Feb 28. PMID: 38428548.
- Compartmentalized ocular lymphatic system mediates eye-brain immunity.Yin X, Zhang S, Lee JH, Dong H, Mourgkos G, Terwilliger G, Kraus A, Geraldo LH, Poulet M, Fischer S, Zhou T, Mohammed FS, Zhou J, Wang Y, Malloy S, Rohner N, Sharma L, Salinas I, Eichmann A, Thomas JL, Saltzman WM, Huttner A, Zeiss C, Ring A, Iwasaki A, Song E. Nature. 2024 Feb 28; 2024 Feb 28. PMID: 38418880.
- Targeting cervical cancer with anti-PD-1 antibodies: what is new?Greenman M, McNamara B, Mutlu L, Santin AD. Expert Opin Biol Ther. 2024 Feb 27; 2024 Feb 27. PMID: 38391293.
- An oxidative photocyclization approach to the synthesis of Securiflustra securifrons alkaloids.Alexander BW, Bartfield NM, Gupta V, Mercado BQ, Del Campo M, Herzon SB. Science. 2024 Feb 23; 2024 Feb 22. PMID: 38386756.
- IL-10 constrains sphingolipid metabolism to limit inflammation.York AG, Skadow MH, Oh J, Qu R, Zhou QD, Hsieh WY, Mowel WK, Brewer JR, Kaffe E, Williams KJ, Kluger Y, Smale ST, Crawford JM, Bensinger SJ, Flavell RA. Nature. 2024 Feb 21; 2024 Feb 21. PMID: 38383790.
- Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.Lin DI, Huang RSP, Ladas I, Keller RB, Patel NR, Lakis S, Decker B, Janovitz T, Mata DA, Ross JS, Vergilio JA, Elvin JA, Herbst RS, Mack PC, Killian JK. Front Oncol. 2024; 2024 Feb 20. PMID: 38444675.
- Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Leukemia. 2024 Feb 20; 2024 Feb 20. PMID: 38378841.
- Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Blood Cancer J. 2024 Feb 20; 2024 Feb 20. PMID: 38378617.
- Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Feb 20; 2024 Feb 20. PMID: 38377304.
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet. 2024 Feb 17; 2024 Jan 18. PMID: 38246194.
- ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Hu B, Wiesehöfer M, de Miguel FJ, Liu Z, Chan LH, Choi J, Melnick MA, Arnal-Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen DX, Politi K. Cancer Res. 2024 Feb 15; 2024 Feb 15. PMID: 38359163.
- The dementia care study (D-CARE): Recruitment strategies and demographic characteristics of participants in a pragmatic randomized trial of dementia care.Yang M, Samper-Ternent R, Volpi E, Green AN, Lichtenstein M, Araujo K, Borek P, Charpentier P, Dziura J, Gill TM, Galloway R, Greene EJ, Lenoir K, Peduzzi P, Meng C, Reese J, Shelton A, Skokos EA, Summapund J, Unger E, Reuben DB, Williamson JD, Stevens AB. Alzheimers Dement. 2024 Feb 15; 2024 Feb 15. PMID: 38358084.
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, Wang C, Brufsky A, LoRusso P, Chung V, Yuan Y, Downs M, O'Connor A, Shin SM, Hernandez A, Engle EL, Piekarz R, Streicher H, Talebi Z, Rudek MA, Zhu Q, Anders RA, Cimino-Mathews A, Fertig EJ, Jaffee EM, Stearns V, Connolly RM. Nat Cancer. 2024 Feb 14; 2024 Feb 14. PMID: 38355777.
- Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury.Chase DH, Bebenek AM, Nie P, Jaime-Figueroa S, Butrin A, Castro DA, Hines J, Linhares BM, Crews CM. Angew Chem Int Ed Engl. 2024 Feb 13; 2024 Feb 13. PMID: 38348945.
- The European Union Ban on Microplastics Includes Artificial Turf Crumb Rubber Infill: Other Nations Should Follow Suit.Zuccaro P, Thompson DC, de Boer J, Llompart M, Watterson A, Bilott R, Birnbaum LS, Vasiliou V. Environ Sci Technol. 2024 Feb 13; 2024 Feb 1. PMID: 38301275.
- Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.McNamara B, Demirkiran C, Hartwich TMP, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter JA, Santin AD. Gynecol Oncol. 2024 Feb 9; 2024 Feb 9. PMID: 38493021.
- Encoding scheme design for gradient-free, nonlinear projection imaging using Bloch-Siegert RF spatial encoding in a low-field, open MRI system.Selvaganesan K, Ha Y, Sun H, Zhang Z, Sun C, Samardzija A, Galiana G, Constable RT. Sci Rep. 2024 Feb 8; 2024 Feb 8. PMID: 38332252.
- Immunotherapy utilization in stage IIIA melanoma: less may be more.Frey AE, Kerekes DM, Khan SA, Tran TT, Kluger HM, Clune JE, Ariyan S, Sznol M, Ishizuka JJ, Olino KL. Front Oncol. 2024; 2024 Feb 6. PMID: 38380358.
- Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.Mezzacappa C, Rossi R, Jaffe A, Taddei TH, Strazzabosco M. Cancer Epidemiol Biomarkers Prev. 2024 Feb 6. PMID: 38059831.
- A comprehensive trial on PFAS remediation: hemp phytoextraction and PFAS degradation in harvested plants.Nason SL, Thomas S, Stanley C, Silliboy R, Blumenthal M, Zhang W, Liang Y, Jones JP, Zuverza-Mena N, White JC, Haynes CL, Vasiliou V, Timko MP, Berger BW. Env Sci Adv. 2024 Feb 5; 2024 Jan 5. PMID: 38322792.
- Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, Bawa'neh H, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan AM. JCO Glob Oncol. 2024 Feb. PMID: 38422464.
- Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy SP, Eder JP, Deng Y, LoRusso P, Kim JW, Patel AA. JCO Precis Oncol. 2024 Feb. PMID: 38412387.
- The importance of considering competing risks in recurrence analysis of intracranial meningioma.Mirian C, Jensen LR, Juratli TA, Maier AD, Torp SH, Shih HA, Morshed RA, Young JS, Magill ST, Bertero L, Stummer W, Spille DC, Brokinkel B, Oya S, Miyawaki S, Saito N, Proescholdt M, Kuroi Y, Gousias K, Simon M, Moliterno J, Prat-Acin R, Goutagny S, Prabhu VC, Tsiang JT, Wach J, Güresir E, Yamamoto J, Kim YZ, Lee JH, Koshy M, Perumal K, Baskaya MK, Cannon DM, Shrieve DC, Suh CO, Chang JH, Kamenova M, Straumann S, Soleman J, Eyüpoglu IY, Catalan T, Lui A, Theodosopoulos PV, McDermott MW, Wang F, Guo F, Góes P, de Paiva Neto MA, Jamshidi A, Komotar R, Ivan M, Luther E, Souhami L, Guiot MC, Csonka T, Endo T, Barrett OC, Jensen R, Gupta T, Patel AJ, Klisch TJ, Kim JW, Maiuri F, Barresi V, Tabernero MD, Skyrman S, Broechner A, Bach MJ, Law I, Scheie D, Kristensen BW, Munch TN, Meling T, Fugleholm K, Blanche P, Mathiesen T. J Neurooncol. 2024 Feb; 2024 Feb 10. PMID: 38336917.
- May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma?Giannini EG, Strazzabosco M. Liver Int. 2024 Feb. PMID: 38289589.
- Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.Bellone S, Siegel ER, Scheim DE, Santin AD. Gynecol Oncol Rep. 2024 Feb; 2024 Jan 4. PMID: 38273933.
- Racial differences in treatment and survival among older patients with multiple myeloma.Wang R, Neparidze N, Ma X, Colditz GA, Chang SH, Wang SY. Cancer Med. 2024 Feb; 2024 Jan 17. PMID: 38234237.
- Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life.Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco JI, Washington SL, Renzulli JF II,, Sprenkle P, Kim IY, Leapman MS. Urol Oncol. 2024 Feb; 2023 Dec 31. PMID: 38161105.
- NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Br J Cancer. 2024 Feb; 2023 Dec 22. PMID: 38135713.
- PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.Kim TK, Han X, Hu Q, Vandsemb EN, Fielder CM, Hong J, Kim KW, Mason EF, Plowman RS, Wang J, Wang Q, Zhang JP, Badri T, Sanmamed MF, Zheng L, Zhang T, Alawa J, Lee SW, Zeidan AM, Halene S, Pillai MM, Chandhok NS, Lu J, Xu ML, Gore SD, Chen L. J Clin Invest. 2024 Feb 1; 2024 Feb 1. PMID: 38060328.
- Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja MA. Bone Marrow Transplant. 2024 Feb; 2023 Nov 16. PMID: 37973893.
- Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg SB. J Thorac Oncol. 2024 Feb; 2023 Oct 6. PMID: 37806385.
- A Physics-Based Algorithm to Universally Standardize Routinely Obtained Clinical T(2)-Weighted Images.Elsaid NMH, Tagare HD, Galiana G. Acad Radiol. 2024 Feb; 2023 Jul 6. PMID: 37407374.
- The Fanconi anemia pathway repairs colibactin-induced DNA interstrand cross-links.Altshuller M, He X, MacKrell EJ, Wernke KM, Wong JWH, Sellés-Baiget S, Wang TY, Chou TF, Duxin JP, Balskus EP, Herzon SB, Semlow DR. bioRxiv. 2024 Jan 31; 2024 Jan 31. PMID: 38352618.
- Integrating the gut microbiome and pharmacology.Verdegaal AA, Goodman AL. Sci Transl Med. 2024 Jan 31; 2024 Jan 31. PMID: 38295186.
- Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst R, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Clin Cancer Res. 2024 Jan 26; 2024 Jan 26. PMID: 38277235.
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. J Thorac Oncol. 2024 Jan 24; 2024 Jan 24. PMID: 38278303.
- Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Lancet. 2024 Jan 20; 2023 Dec 1. PMID: 38048786.
- Synthesis of N-Acylsulfenamides from (Hetero)Aryl Iodides and Boronic Acids by One-Pot Sulfur-Arylation and Dealkylation.Greenwood NS, Cerny NP, Deziel AP, Ellman JA. Angew Chem Int Ed Engl. 2024 Jan 15; 2023 Dec 12. PMID: 38015869.
- Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.Gross M, Huber S, Arora S, Ze'evi T, Haider SP, Kucukkaya AS, Iseke S, Kuhn TN, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Jan 13; 2024 Jan 13. PMID: 38217704.
- The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, Zhang D, Dragovich PS, Pillow T, Wei B, Sadowsky J, Leipold D, Wilson T, Kamath A, Mamounas M, Lee MV, Saad O, Choeurng V, Ungewickell A, Monemi S, Crocker L, Kalinsky K, Modi S, Jung KH, Hamilton E, LoRusso P, Krop I, Schutten MM, Commerford R, Sliwkowski MX, Cho E. Nat Commun. 2024 Jan 11; 2024 Jan 11. PMID: 38212321.
- Low-Field, Low-Cost, Point-of-Care Magnetic Resonance Imaging.Samardzija A, Selvaganesan K, Zhang HZ, Sun H, Sun C, Ha Y, Galiana G, Constable RT. Annu Rev Biomed Eng. 2024 Jan 11; 2024 Jan 11. PMID: 38211326.
- OPLS/2020 Force Field for Unsaturated Hydrocarbons, Alcohols, and Ethers.Jorgensen WL, Ghahremanpour MM, Saar A, Tirado-Rives J. J Phys Chem B. 2024 Jan 11; 2023 Dec 21. PMID: 38127719.
- Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships.Herbst RS, Blanke CD, Sigal EV. Clin Cancer Res. 2024 Jan 5. PMID: 37903180.
- A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MÁ, Couselo EM, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez-Cao M, Arance A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, Kluger HM. Clin Cancer Res. 2024 Jan 5. PMID: 37535056.
- A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.Garralda E, Schram AM, Bedard PL, Schwartz GK, Yuen E, McNeely SC, Ribeiro S, Cunningham J, Wang Y, Urunuela A, Xu X, LoRusso P. Oncologist. 2024 Jan 5. PMID: 37531083.
- Dynamic metabolism of endothelial triglycerides protects against atherosclerosis in mice.Boutagy NE, Gamez-Mendez A, Fowler JW, Zhang H, Chaube BK, Esplugues E, Kuo A, Lee S, Horikami D, Zhang J, Citrin KM, Singh AK, Coon BG, Lee MY, Suarez Y, Fernandez-Hernando C, Sessa WC. J Clin Invest. 2024 Jan 4; 2024 Jan 4. PMID: 38175710.
- Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.Kerekes DM, Frey AE, Prsic EH, Tran TT, Clune JE, Sznol M, Kluger HM, Forman HP, Becher RD, Olino KL, Khan SA. JAMA Oncol. 2024 Jan 4; 2024 Jan 4. PMID: 38175659.
- Celebrating 20 years of human genomics: a journey of discovery.Vasiliou V. Hum Genomics. 2024 Jan 2; 2024 Jan 2. PMID: 38163870.
- Telemedicine and Cancer: Shifting a Paradigm of Care.Chiang AC. Cancer J. 2024 Jan-Feb 01. PMID: 38265918.
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Lancet Haematol. 2024 Jan. PMID: 38135371.
- Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective.Kantarjian H, Zeidan AM, Fathi AT, Stein E, Rajkumar V, Tefferi A. Mayo Clin Proc. 2024 Jan; 2023 Dec 16. PMID: 38108685.
- Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.Majem M, Basch E, Cella D, Garon EB, Herbst RS, Leighl NB. Lung Cancer. 2024 Jan; 2023 Nov 10. PMID: 38070301.
- Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Lancet Haematol. 2024 Jan; 2023 Dec 5. PMID: 38065203.
- Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Han SW. Nat Med. 2024 Jan; 2023 Dec 5. PMID: 38052910.
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM. Ann Hematol. 2024 Jan; 2023 Dec 1. PMID: 38036712.
- A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP. Leukemia. 2024 Jan; 2023 Nov 7. PMID: 37935977.
- Post-transplantation cyclophosphamide is associated with increased bacterial infections.Ustun C, Chen M, Kim S, Auletta JJ, Batista MV, Battiwalla M, Cerny J, Gowda L, Hill JA, Liu H, Munshi PN, Nathan S, Seftel MD, Wingard JR, Chemaly RF, Dandoy CE, Perales MA, Riches M, Papanicolaou GA. Bone Marrow Transplant. 2024 Jan; 2023 Oct 31. PMID: 37903992.
- Long-term super-resolution inner mitochondrial membrane imaging with a lipid probe.Zheng S, Dadina N, Mozumdar D, Lesiak L, Martinez KN, Miller EW, Schepartz A. Nat Chem Biol. 2024 Jan; 2023 Oct 19. PMID: 37857992.
- A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.Merryman RW, Redd RA, Freedman AS, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Ng S, Odejide OO, Parry EM, Isufi I, Kline J, Cohen JB, Mehta-Shah N, Bartlett NL, Mei M, Kuntz TM, Wolff J, Rodig SJ, Armand P, Jacobson CA. Ann Hematol. 2024 Jan; 2023 Oct 18. PMID: 37851072.
- Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery.Paiella S, Secchettin E, Lionetto G, Archibugi L, Azzolina D, Casciani F, Simeone DM, Overbeek KA, Goggins M, Farrell J, Ponz de Leon Pisani R, Tridenti M, Corciulo MA, Malleo G, Arcidiacono PG, Falconi M, Gregori D, Bassi C, Salvia R, Capurso G. Ann Surg. 2024 Jan 1; 2023 Sep 8. PMID: 37681303.
- Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Smalley I, Boire A, Brastianos P, Kluger HM, Hernando-Monge E, Forsyth PA, Ahmed KA, Smalley KSM, Ferguson S, Davies MA, Glitza Oliva IC. Pigment Cell Melanoma Res. 2024 Jan; 2023 Aug 25. PMID: 37622466.
- Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease.Fouda RT, Cherukury HM, Kiven SB, Garcia NR, Argueta DA, Velasco GJ, Gupta K, Roberts JD. Haematologica. 2024 Jan 1; 2024 Jan 1. PMID: 37534545.
- Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience.Ivanics T, Claasen MPAW, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ. Ann Surg. 2024 Jan 1; 2023 Jul 31. PMID: 37522174.
2023
- European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care.Carbone M, Neuberger J, Rowe I, Polak WG, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu GC, Strazzabosco M, Cillo U. Transpl Int. 2023; 2024 Jan 25. PMID: 38332850.
- Visible-Light-Mediated, Diastereoselective Epimerization of Exocyclic Amines.Vargas-Rivera MA, Liu AS, Ellman JA. Org Lett. 2023 Dec 29; 2023 Dec 19. PMID: 38114418.
- Introduction: Remote and Late Stage Functionalization.Miller SJ, Ritter T. Chem Rev. 2023 Dec 27. PMID: 38148744.
- Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas.Tillmanns N, Lost J, Tabor J, Vasandani S, Vetsa S, Marianayagam N, Yalcin K, Erson-Omay EZ, von Reppert M, Jekel L, Merkaj S, Ramakrishnan D, Avesta A, de Oliveira Santo ID, Jin L, Huttner A, Bousabarah K, Ikuta I, Lin M, Aneja S, Turowski B, Aboian M, Moliterno J. Sci Rep. 2023 Dec 22; 2023 Dec 22. PMID: 38135704.
- Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. J Clin Pharmacol. 2023 Dec 17; 2023 Dec 17. PMID: 38105505.
- Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase.Prucha GR, Henry S, Hollander K, Carter ZJ, Spasov KA, Jorgensen WL, Anderson KS. Eur J Med Chem. 2023 Dec 15; 2023 Oct 20. PMID: 37883896.
- CLINICAL PREDICTIVE VALUE OF RENALASE IN POST-ERCP PANCREATITIS.Muniraj T, Desir G, Gorelick FS, Guo X, Ciarleglio M, Deng Y, Jamidar PA, Farrell JJ, Aslanian HR, Laine L. Gastrointest Endosc. 2023 Dec 14; 2023 Dec 14. PMID: 38103747.
- Ensemble Geometric Deep Learning of Aqueous Solubility.Ghahremanpour MM, Saar A, Tirado-Rives J, Jorgensen WL. J Chem Inf Model. 2023 Dec 11; 2023 Nov 21. PMID: 37990484.
- Self-Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma.Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. CNS Neurosci Ther. 2023 Dec 4; 2023 Dec 4. PMID: 38044793.
- Sex differences in the effects of trait anxiety and age on resting-state functional connectivities of the amygdala.Chaudhary S, Hu S, Hu K, Dominguez JC, Chao HH, Li CR. J Affect Disord Rep. 2023 Dec; 2023 Aug 28. PMID: 38105798.
- When to use which molecular prognostic scoring system in the management of patients with MDS?Kewan T, Bewersdorf JP, Gurnari C, Xie Z, Stahl M, Zeidan AM. Best Pract Res Clin Haematol. 2023 Dec; 2023 Oct 17. PMID: 38092484.
- Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.Scheim DE, Vottero P, Santin AD, Hirsh AG. Int J Mol Sci. 2023 Dec 1; 2023 Dec 1. PMID: 38069362.
- Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID.Bellone S, Siegel EE, Santin AD. Gynecol Oncol Rep. 2023 Dec; 2023 Nov 2. PMID: 38029227.
- Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Lung Cancer. 2023 Dec; 2023 Nov 13. PMID: 37995456.
- Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists.Madanat YF, Zeidan AM. Clin Lab Med. 2023 Dec; 2023 Aug 8. PMID: 37865511.